BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29426276)

  • 1. Rare MYC-amplified Neuroblastoma With Large Cell Histology.
    Matsuno R; Gifford AJ; Fang J; Warren M; Lukeis RE; Trahair T; Sugimoto T; Marachelian A; Asgharzadeh S; Maris JM; Ikegaki N; Shimada H
    Pediatr Dev Pathol; 2018; 21(5):461-466. PubMed ID: 29426276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group.
    Kawano A; Hazard FK; Chiu B; Naranjo A; LaBarre B; London WB; Hogarty MD; Cohn SL; Maris JM; Park JR; Gastier-Foster JM; Ikegaki N; Shimada H
    Am J Surg Pathol; 2021 Aug; 45(8):1075-1081. PubMed ID: 33739795
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Zimmerman MW; Liu Y; He S; Durbin AD; Abraham BJ; Easton J; Shao Y; Xu B; Zhu S; Zhang X; Li Z; Weichert-Leahey N; Young RA; Zhang J; Look AT
    Cancer Discov; 2018 Mar; 8(3):320-335. PubMed ID: 29284669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
    Shimada H; Stram DO; Chatten J; Joshi VV; Hachitanda Y; Brodeur GM; Lukens JN; Matthay KK; Seeger RC
    J Natl Cancer Inst; 1995 Oct; 87(19):1470-6. PubMed ID: 7674334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implication of unfavorable histology, MYCN amplification and diploidy for stage I and II neuroblastomas.
    de Buys Roessingh AS; Rougemont AL; Wiesenauer C; Barrette S; Bouron-Dal Soglio D; Lallier M
    Eur J Pediatr Surg; 2008 Dec; 18(6):410-4. PubMed ID: 19012235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivo.
    VanDevanter DR; Piaskowski VD; Casper JT; Douglass EC; Von Hoff DD
    J Natl Cancer Inst; 1990 Dec; 82(23):1815-21. PubMed ID: 2250296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma.
    Cohn SL; Rademaker AW; Salwen HR; Franklin WA; Gonzales-Crussi F; Rosen ST; Bauer KD
    Am J Pathol; 1990 May; 136(5):1043-52. PubMed ID: 2349963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
    Weber A; Starke S; Bergmann E; Christiansen H
    Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
    Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
    Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human neuroblastoma cell lines that express N-myc without gene amplification.
    Wada RK; Seeger RC; Brodeur GM; Einhorn PA; Rayner SA; Tomayko MM; Reynolds CP
    Cancer; 1993 Dec; 72(11):3346-54. PubMed ID: 8242562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYCN protein expression as a predictor of neuroblastoma prognosis.
    Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
    Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?--An overview.
    Tsuchida Y; Hemmi H; Inoue A; Obana K; Yang HW; Hayashi Y; Kanda N; Shimatake H
    Tumour Biol; 1996; 17(2):65-74. PubMed ID: 8658015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of N-myc oncogene in stage II and IVS neuroblastomas may be a prognostic indicator.
    Nakagawara A; Ikeda K; Tsuda T; Higashi K; Okabe T
    J Pediatr Surg; 1987 May; 22(5):415-8. PubMed ID: 3585663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.
    Castle VP; Heidelberger KP; Bromberg J; Ou X; Dole M; Nuñez G
    Am J Pathol; 1993 Dec; 143(6):1543-50. PubMed ID: 8256847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
    Manohar CF; Salwen HR; Brodeur GM; Cohn SL
    Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.